Efficacy of Oral versus Intravenous Vitamin C on Serum Oxalate Level in Hemodialysis Patients

Document Type : Research Paper



increase the risk of cardiac, vascular and bone diseases. Hemodialysis patients (HD) are at high risk for Scurvy disease due to dietary limitation and ascorbic acid losses through dialysis. Vitamin C also decreases HTN and accelerated arthrosclerosis. Thus, vitamin C supplementation is necessary for these patients. The aim of this study was to evaluate efficacy of oral versus intravenous vitamin C on serum oxalate level in hemodialysis patients.
Material and Methods: This clinical-trial study was done on hemodialysis patients referred to the three treatment centers of Mazandaran Province. 41 HD patients, who had not consumed vitamin C for two months, were randomly divided into two groups, oral and intravenous. In intravenous (IV AA) group, vitamin C 500 mg/day was administered three times a week; and oral group received vitamin C 125 mg/day for two months. Oxalate serum level was measured before and after treatment. Individual, laboratory, and treatment complication data were gathered in a questionnaire. Intra group comparison was done with t-student test and inter group comparison was done with independent– sample t-test. Data were expressed as SE± Mean and p-valueResults: Serum oxalate level in each group increased, there was no significant differences intra group and between two groups (p= 0.3) (in oral, from 1.8±0.4mgl/L to 1.85±0.8mgl/L, P=0.4 and in IVAA from 1.8±0.7mg/L to 2.1±0.9mg/L, P=0.3).
Conclusion: Oral and IV AA in the used dosage did not increase serum oxalate level and were safe to use as supplementation in HD patients.


1- Alkhunaizi A, Chan L. Secondary oxalosis: a cause of delayed recovery of renal functional in the setting of acute
renal failure . J am societ Nephrol 1996 7:2320-2360.
2- Thmpson C. Relationship Between vitamin C intake an increasing oxalosis. Seminars in Dialysis 1988, 1(2):94-98.
3- Ogawa Y,Machida N, Masahide J, Gakiya M, Chinen Y,Oda M, et al.Major factors modulation the serum
oxalic acid level in hemodialysis patients. Frotiers in Bioscience 2004 Sep; 9:2901-2908.
4- Ono K. Secondary hyperoxalemia caused by vitamin c supplementation in regular hemodialysis patients.Clin
Nephrol 1986; 26:239-243.
5- Melendez O. Intravenous vitamin C for Erythropoietin resistance Patient. Semin Dial 2002; 13:335-360.
6-Descombres E, Hanck AB,Fellay G. Water soluble vitamins in chronic hemodialysis patients.Kideny Int
7-Tarng D,Wei Y,Huang T,Kuo T, Yang W.Intravenous ascorbic acid as an adjuvant therapy for recombinant
erythropoietin in hemodialysis patients with hyperferritinemia.Kidney Inter 1999 ;55:2477-2486.
8 - Canvese C,Petrarulo M,Massarenti P, Berutti S, Fenoglio R,Pauletto D ,Lanfranco G,BergamoD,Sandri I,Marangella
M.long – term ,intravenous vitamin c leads to plasma calcium oxalate supersaturation in hemodialysis patients.Clin
Nephrol 1989;31:31-34.
9-Pru C,Eaton J,Kjellstrand C.Vitamin c intoxication and hyperoxalemia in chronic hemodialysis patient.Nephrol 39
10-Chan D,Irish A,Dogra G,Efficacy and safety of oral versus intravenous ascorbic acid for anemia in hemodialysis
patients.Nephrol 2005;10:336-340.
11-Kalantar-zadeh K,Kopple JD, Deepak S, Block D, Block G. Food intake characteristics of hemodialysis patients
as obtained by food frequent questionnaire. J Ren Nutr 2002; 12:17-31.